teduglutide

Subscribe to Selected New Research on teduglutide

7 relevant articles (0 outcomes, 1 trials/studies) found for this Bio-Agent

Description: glucagon-like peptide 2 (GLP-2) analog; protects small intestinal stem cells from radiation damage

Also Known As:

(Gly2)GLP-2; Gly(2)-GLP-2

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Peptides: 16074

teduglutide: 7

Experts

1.	Scolapio, James S: 1 article (06/2006)
2.	Ferrone, Marcus: 1 article (06/2006)
3.	Buchman, A: 1 article (09/2005)
4.	Sanguinetti, E L: 1 article (09/2005)
5.	Gregory, J: 1 article (09/2005)
6.	Holst, J: 1 article (09/2005)
7.	Tappenden, K A: 1 article (09/2005)
8.	Jeppesen, P B: 1 article (09/2005)
9.	Scolapio, J S: 1 article (09/2005)
10.	Mortensen, P B: 1 article (09/2005)

Related Diseases

1.	Short Bowel Syndrome 06/01/2008 - "Based on the results of the few Phase II studies and the preliminary results of a Phase III trial, teduglutide at doses of 0.05 or 0.10 mg/kg/day may improve many clinical, laboratory and histologic abnormalities in short bowel syndrome patients" 06/01/2008 - "CONCLUSION: Teduglutide is a first-in-class therapy with the potential to create a new standard of care for patients suffering from short bowel syndrome" 06/01/2008 - "AIM: To provide an update on the recent advances on the use of teduglutide in patients with short bowel syndrome" 06/01/2006 - "Teduglutide for the treatment of short bowel syndrome." 06/01/2006 - "OBJECTIVE: To summarize the pharmacology, development, and clinical application of teduglutide (ALX-0600), a glucagon-like peptide-2 (GLP-2) analog for the treatment of short bowel syndrome (SBS)" Get all the results and reference details, order at left...
2.	Mucositis 12/01/2004 - "These results suggest that teduglutide has the ability to modulate clonogenic stem cell survival in the small intestine and this may have a useful clinical application in the prevention of cancer therapy-induced mucositis." Get all the results and reference details, order at left...
3.	Pain (Aches) 11/01/2008 - "No relationship between teduglutide treatments and frequency of adverse events was observed, with the exception of injection site pain, which increased as a function of dose and injected volume" Get all the results and reference details, order at left...
4.	Neoplasms (Cancer) 12/01/2004 - "These results suggest that teduglutide has the ability to modulate clonogenic stem cell survival in the small intestine and this may have a useful clinical application in the prevention of cancer therapy-induced mucositis." Get all the results and reference details, order at left...
5.	Influenza in Birds (Avian Flu) 01/01/2007 - "This issues focuses on the following selection of drugs: 4'-Thio-ara-C, 5-methyltetrahydrofolate; ABT-089, AD-237, AF-37702, alvocidib hydrochloride, apricitabine, armodafinil, atrasentan, AVE-5883, avian influenza vaccine, azimilide hydrochloride; Banoxantrone, BIBF-1120; CD34+ cells, certolizumab pegol, CHIR-258, cilansetron, CoFactor, CX-3543, cystemustine; D-003, dexloxiglumide, DMXB-anabaseine; Ecogramostim, elcometrine, elcometrine/ethinylestradiol, etravirine; Fenretinide, fingolimod hydrochloride, fospropofol disodium; Gaboxadol, gestodene, glutamine; Human insulin, hyaluronic acid; Incyclinide, indacaterol, ispronicline, istradefylline; Labradimil, lamifiban, lapatinib, L-arginine hydrochloride, liposomal cisplatin, liposome encapsulated paclitaxel, LY-517717; Manidipine hydrochloride/delapril hydrochloride, maraviroc, MBP(82-98), MD-0727, MDX-214, melanotan I, MMR vaccine; Nacystelyn, nalfurafine hydrochloride, nibentan, nilotinib, NK-105; OBI-1, oblimersen sodium, olmesartan medoxomil, olmesartan medoxomil/hydrochlorothiazide, oregovomab; Pexelizumab, PG-116800, PG-CPT, PHA-794428, prasugrel; RC-3095, rDNA insulin, RFB4(dsFv)-PE38, rhEndostatin, rhenium Re-186 etidronate, rhGM-CSF, roflumilast, romidepsin; Sarcosine, SGLU1, SGN-40, succinobucol; TAU, teduglutide, telatinib, tesofensine, tipifarnib, tirapazamine, TKA-731, tolvaptan, trabectedin; Vaccimel, vatalanib succinate, velafermin, vildagliptin, vinflunine; XP-19986; YM-155." Get all the results and reference details, order at left...
7 Diseases and 7 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Paclitaxel (Taxol)
2.	Glucagon (Glukagon)
3.	4- methyl- N- (3- (4- methylimidazol- 1- yl)- 5- (trifluoromethyl)phenyl)- 3- ((4- pyridin- 3- ylpyrimidin- 2- yl)amino)benzamide (nilotinib)
4.	succinobucol (AGI 1067)
5.	oblimersen (G3139)
6.	prasugrel
7.	Glucagon-Like Peptide 2
8.	Interleukin 1 Receptor Antagonist Protein (Anakinra)
9.	Measles-Mumps-Rubella Vaccine (MMR Vaccine)
10.	Sirolimus (Rapamycin)
159 Drugs and Important Bio-Agents and 5 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Stents
1 Therapies and Procedures and 1 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>